About the Authors
Craig Kimble, PharmD, MBA, MS, BCACP, is director of experiential learning, manager of clinical support services, and associate professor in the Department of Pharmacy Practice, Administration, and Research at Marshall University School of Pharmacy in Huntington, West Virginia.
Thomas Pile, PharmD, CDCES, is a clinical assistant professor in the Department of Pharmacy Practice, Administration, and Research at Marshall University School of Pharmacy in Huntington, West Virginia.
The pharmaceutical industry serves a critical role in providing safe and effective medications to patients globally. The industry faces persistent challenges, notably proliferation of counterfeit medications and, now, drug importation challenges.1 In fact, counterfeiting and trafficking medications has become one of the fastest-growing criminal enterprises globally, with an estimated $431 billion generated by criminals worldwide.2 In developing countries, a study done by the World Health Organization found that counterfeit medications are now a major cause of death in children.3
Recently, the FDA reported that counterfeit semaglutide (Ozempic; Novo Nordisk) was found in the legitimate US drug supply chain; the FDA seized thousands of units of product as a result.4 Similarly, Gilead Sciences issued a statement on efforts the company is taking to halt distribution of counterfeit HIV medications.5 These examples indicate that despite current regulatory measures in the US, counterfeit products are still making their way into the supply chain, potentially containing dangerous substances.6
Securing the Drug Channel Within the US
To improve security of the supply chain of pharmaceuticals within the US and protect consumers from counterfeit medications, the Drug Supply Chain and Security Act (DSCSA) was passed in 2013, accompanied by phased implementation requirements unfolding over subsequent years. For 2023 and beyond, enhanced product tracing at the individual package level is required. However, the FDA announced a 1-year delay (from November 27, 2023, to November 27, 2024) in implementing the new electronic prescription tracking and tracing system in the DSCSA.7-9 These administrative rules are intended to allow the use of serialized electronic tracing mechanisms to track prescription drugs as they move throughout the supply chain.10 Eventually, this should help improve the removal of dangerous counterfeit drugs.
DSCSA Implementation
DSCSA required phased implementation and the following changes8:
- Phase 1: Wholesale distributors, repackagers, dispensers, and other third-party logistics providers are required to implement interoperable and electronic tracing of prescription products at the individual package level. Also, supply chain partners are expected to accept saleable returns that are unable to comply with new regulations.
- Phase 2: Products are to be handled and traced by using serialization of all pharmaceutical products, converting product information into alphanumeric sequences.
- Phase 3: Wholesale distributors and third-party logistics providers are to send annual licensed reports to the FDA, as well as reports of suspicious products. This can be done through the FDA’s Center for Drug Evaluation and Research NextGen portal.
The implementation delay for DSCSA was a result of the supply chain not being completely ready for implementation. Many distributors questioned exactly what and how much tracing information needed to be supplied to state and federal authorities and how many resources were needed to comply. They also questioned what to do with nonserialized products in the supply chain.8,10